Separate the visit from the medicine
Begin with the concern that brought you here. Then compare the conversation, the product and the practical details separately.
- Name the health concern you want to discuss.
- Separate the visit from the proposed medicine.
- Keep the pharmacy and payment questions open.
Put a name to the thing being offered
Insulin belongs to the peptide family: these are short chains of protein’s building blocks.
Get the exact name
That broad word is a starting point for a conversation, rather than a product description. Ask for the exact name of the substance. Then ask what form is proposed, such as an injection or a tablet. Keep those words in your notes so that the next person you speak with can answer the same question.
In the record checked in September 2026, a peptide name alone establishes neither safety nor legal status.
Identify the care roles
The person assessing you is called a clinician. That may be a doctor or nurse. Ask who will read your answers and discuss your concerns. The prescriber can order medication, and the pharmacy fills the order. Those roles may appear together on a website, but ask who is doing each job.
Compare the visit before the product
Telehealth means having the care discussion at a distance. That might involve video, a phone call or messages. For an in-person visit, the assessment happens with both of you in the room. Think about which setting lets you explain your concern and ask your own questions.
Remote assessments need the same professional care standard as office visits, the medical boards’ federation says.
State medical boards belong to this federation. Its policy helps guide their work; enforceable rules come from each state. The practical question is simple: can this format do the assessment that your concern calls for?
Permission to treat you depends on your location during the appointment. Under the rules checked in September 2026, they need that state’s license or other legal permission to practice there.
If travel is part of your plans, mention where you expect to be. If the clinician does not hold that state’s license, ask what permission allows the visit and how to verify it with the state’s licensing board. A familiar website name does not answer that question.
Ask which product category applies
Tirzepatide and semaglutide are medicine names. FDA’s September 2026 record includes approved injections of both. Tirzepatide treats type 2 diabetes under the Mounjaro name; the Zepbound version is for long-term weight management. With semaglutide, Ozempic is used for type 2 diabetes. Wegovy is approved to reduce weight and help maintain the loss long term. These are examples of their approved uses; the brands have different uses and requirements.
The FDA is the Food and Drug Administration, the federal drug agency. Ask which specific product and use the clinician means, rather than treating an entire family of drugs as the same choice.
Compounding means mixing or changing a medicine to meet a person’s specific need, instead of supplying the finished factory product.
A compounded preparation has no FDA approval; that remained the distinction in September 2026 even when a licensed pharmacy made it.
A research disclaimer describes the product as a chemical for experiments, rather than personal treatment. Common wording includes “research use only.” Another version says “not for human consumption.” In the warning letters checked for September 2026, FDA said the label did not change evidence that sellers were promoting drugs for people.
Keep the product category beside its exact name. For a custom preparation, ask why the change is needed for your concern and who will make it. For a manufactured drug, ask which approved product the clinician means.
Leave with a short written comparison
Write the same headings for each route: who evaluates me, what is proposed, who fills it, what I pay and who answers later. Leave a space wherever the answer is missing. A blank in your notes is a useful next question, not a reason to guess.
Choose your questions